tiprankstipranks
Trending News
More News >
Zynex Inc (ZYXIQ)
OTHER OTC:ZYXIQ
US Market

Zynex (ZYXIQ) Price & Analysis

Compare
854 Followers

ZYXIQ Stock Chart & Stats

$0.10
-$0.09(-1.11%)
At close: 4:00 PM EST
$0.10
-$0.09(-1.11%)

Bulls Say, Bears Say

Bulls Say
Leadership ChangeSteven Dyson, with over 25 years of experience in the medical technology sector, has been appointed as CEO to refocus Zynex's business strategy and return it to a strong growth trajectory.
Market ExpansionNiCO, if cleared by the FDA, would allow Zynex to enter the $2.8 billion pulse oximetry market with differentiating precision and accuracy in hospital and non-hospital settings.
Bears Say
Potential DilutionPotential dilution risk is noted as a concern for Zynex's stock value.
Regulatory RisksRisks include slower-than-anticipated revenue growth due to competition and inability to secure regulatory clearance for other medical devices.
Revenue DeclineTotal revenue was $22.3M, representing 55% YoY decline and missing our projection of $27.0M.

ZYXIQ FAQ

What was Zynex Inc’s price range in the past 12 months?
Zynex Inc lowest stock price was $0.06 and its highest was $8.45 in the past 12 months.
    What is Zynex Inc’s market cap?
    Zynex Inc’s market cap is $2.64M.
      When is Zynex Inc’s upcoming earnings report date?
      Zynex Inc’s upcoming earnings report date is Feb 26, 2026 which is in 36 days.
        How were Zynex Inc’s earnings last quarter?
        Zynex Inc released its earnings results on Nov 17, 2025. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$1.23.
          Is Zynex Inc overvalued?
          According to Wall Street analysts Zynex Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Zynex Inc pay dividends?
            Zynex Inc pays a Notavailable dividend of $0.091 which represents an annual dividend yield of N/A. See more information on Zynex Inc dividends here
              What is Zynex Inc’s EPS estimate?
              Zynex Inc’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Zynex Inc have?
              Zynex Inc has 30,388,636 shares outstanding.
                What happened to Zynex Inc’s price movement after its last earnings report?
                Zynex Inc reported an EPS of -$1.42 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -25.664%.
                  Which hedge fund is a major shareholder of Zynex Inc?
                  Currently, no hedge funds are holding shares in ZYXIQ
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Zynex Inc

                    Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

                    Zynex (ZYXIQ) Earnings & Revenues

                    ZYXIQ Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Henry Schein
                    Prestige Consumer Healthcare
                    Guardian Pharmacy Services, Inc. Class A
                    Wellgistics Health Inc

                    Ownership Overview

                    42.96%3.89%1.23%49.15%
                    42.96% Insiders
                    1.23% Other Institutional Investors
                    49.15% Public Companies and
                    Individual Investors
                    Popular Stocks